[F-18 fluorodeoxyglucose positron emission tomography in lung lesions].
Positron emission tomography (PET) is used in an increasing number of patients for the evaluation of solitary pulmonary nodes as well as for staging and restaging of lung cancer. It adds metabolic information to the anatomical images of CT and may lead to significant cost savings as well in primary diagnostics as in restaging if patients are carefully selected.
Peschina
W
W
Abteilung für Nuklearmedizin, Landeskrankenhaus Feldkirch, Carinagasse 47, A-6800 Feldkirch. William.Peschina@lkhf.at
D002283:Carcinoma, Bronchogenic / Q000000981:diagnostic imaging* / Q000191:economics / Q000473:pathology / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging / Q000191:economics / Q000473:pathology / Q000628:therapy; D018288:Carcinoma, Small Cell / Q000000981:diagnostic imaging / Q000191:economics / Q000473:pathology / Q000628:therapy; D003362:Cost-Benefit Analysis; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000191:economics / Q000473:pathology / Q000628:therapy; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging / Q000473:pathology; D009367:Neoplasm Staging; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed / Q000191:economics
D019788:Fluorodeoxyglucose F18